Trials / Completed
CompletedNCT04158687
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 326 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-692 | Administered as powder for oral solution. |
| DRUG | Placebo | Administered as powder for oral solution. |
Timeline
- Start date
- 2019-11-26
- Primary completion
- 2020-12-22
- Completion
- 2020-12-22
- First posted
- 2019-11-12
- Last updated
- 2023-12-22
- Results posted
- 2023-12-22
Locations
26 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04158687. Inclusion in this directory is not an endorsement.